# High Dose Atorvastatin for Preventing Contrast-induced Nephropathy

> **NCT02114346** · PHASE2,PHASE3 · COMPLETED · sponsor: **Isfahan University of Medical Sciences** · enrollment: 250 (actual)

## Conditions studied

- Contrast-Induced Nephropathy

## Interventions

- **DRUG:** Atorvastatin
- **DRUG:** Placebo
- **DRUG:** 0.9% sodium chloride

## Key facts

- **NCT ID:** NCT02114346
- **Lead sponsor:** Isfahan University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2014-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02114346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02114346, "High Dose Atorvastatin for Preventing Contrast-induced Nephropathy". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02114346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*